Image

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

Recruiting
4-12 years
All
Phase N/A

Powered by AI

Overview

This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities.

Participants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches.

The purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available.

This study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.

Description

Children with neurodevelopmental disorders often present with complex impairments affecting motor function, sensory processing, communication, attention, emotional regulation, and daily living skills. These conditions may arise from acquired neurologic injury (such as hypoxic ischemic encephalopathy or traumatic brain injury) or from genetic and chromosomal abnormalities (such as Down syndrome, Rett syndrome, or other genomic disorders).

Traditional therapy models delivered at low frequency may not fully address the intensity required to drive meaningful neuroplastic change. Intensive, high frequency, and multimodal rehabilitation approaches have been proposed as a strategy to enhance neural adaptation by increasing repetition, engagement, and cross-modal stimulation within a short time period.

This observational study is designed to systematically characterize real world outcomes associated with a two week pediatric intensive therapy model that integrates multiple therapeutic modalities tailored to the individual child.

This is a prospective observational study of pediatric participants enrolled in an intensive therapy program. No randomization or experimental intervention is introduced as part of the study. All therapies are delivered as part of routine clinical care.

Participants attend therapy sessions for approximately 2.5 hours per day, 5 days per week, for 2 consecutive weeks.

Therapy is individualized and may include a combination of:

  • Sensory integration techniques
  • Motor planning and coordination activities
  • Reflex integration exercises
  • Oculomotor and visual processing training
  • Auditory processing activities
  • Executive functioning tasks
  • Communication support strategies
  • Emotional regulation training
  • Brain based and neurodevelopmental exercises

Additional modalities such as vibration, tactile stimulation, and photobiomodulation may be used at the discretion of the treating clinician.

This study aims to generate real world evidence on the potential benefits of intensive, individualized, multimodal neurorehabilitation in children with complex neurodevelopmental conditions, including those with genetic and chromosomal etiologies. Findings may inform future controlled studies and help guide clinical decision making for therapy intensity and program design.

Eligibility

Inclusion Criteria:

  • Pediatric participants between approximately 4 and 12 years of age at the time of enrollment.
  • Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to:
    • cerebral palsy
    • autism spectrum disorder
    • developmental delay
    • hypoxic ischemic encephalopathy (HIE)
    • traumatic brain injury
    • sensory processing disorder
    • chromosomal or genetic abnormalities
    • Demonstrate functional impairments in one or more neurodevelopmental domains, including:
  • motor coordination or motor planning
  • sensory processing
  • attention or executive functioning
  • oculomotor or visual processing
  • communication
  • emotional or behavioral regulation
  • activities of daily living
  • Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day/ 5 days per week
    • Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures.
    • Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable.

Exclusion Criteria:

  • Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program.
  • Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician.
  • Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support.
  • Inability to attend or complete the full two-week intensive program.
  • Lack of sufficient baseline or post-intervention data to assess change in functional performance.
  • Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.

Study details
    Neurodevelopmental Disorders
    Neurodevelopmental Disorders (NDD)
    Neurodevelopmental Disorders and Developmental Abnormalities
    Developmental Delay (Disorder)
    Cerebral Palsy (CP)
    Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders
    Neurologic Postural Balance Impairment
    Cerebral Palsy Infantile
    Cerebral Palsy Spastic Hemiplegic
    Cerebral Palsy
    Dyskinetic
    Autism Spectrum Disorder
    Autism Spectrum Disorder (ASD
    Hypoxic Ischemic Encephalopathy
    Hypoxic Ischemic Encephalopathy (HIE)
    Traumatic Brain Injury (TBI)
    Sensory Processing Disorder
    Chromosomal Abnormalities
    Genetic Disorders
    Down Syndrome (Trisomy 21)
    Fragile X Syndrome (FXS)
    RETT Syndrome With Proven MECP2 Mutation
    Williams Syndrome
    22q11.2 Deletion Syndrome
    Sensorimotor Integration

NCT07493096

Healing Hope International

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.